{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-007044","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2023-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.764866+00:00","generated_at":"2026-06-10T01:33:39.930217+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Sonoma Pharmaceuticals provides updated investor presentation; no material changes disclosed","bullets":["Exhibit 99.1 contains an updated corporate presentation dated October 2023.","Presentation reiterates focus on stabilized hypochlorous acid products across multiple therapeutic areas.","Company states products sold directly or via partners in 55 countries.","No new financial guidance, product approvals, or strategic transactions disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-007044","json":"https://secwatch.observer/filing/0001683168-23-007044.json","markdown":"https://secwatch.observer/filing/0001683168-23-007044.md","text":"https://secwatch.observer/filing/0001683168-23-007044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823007044/0001683168-23-007044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316823007044/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T01:33:39.930217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}